SCHEMBL7047239

SCHEMBL7047239

CCP(=O)(O)OC(CCCCC(=O)O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
FFAR4 Q5NUL3 2/20 0.41
FFAR1 O14842 2/20 0.41
FOLH1 Q04609 1/20 0.40
AKR1B1 P15121 1/20 0.38
GPR84 Q9NQS5 7/20 0.37
PPARG P37231 6/20 0.37
PPARD Q03181 6/20 0.37
PPARA Q07869 6/20 0.37
HDAC11 Q96DB2 5/20 0.37
TSHR P16473 4/20 0.37
TLR2 O60603 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
FABP4 P15090 2/20 0.37
PTPN1 P18031 2/20 0.37
SLC22A6 Q4U2R8 1/20 0.37
SLC22A8 Q8TCC7 1/20 0.37
MEN1 O00255 1/20 0.37
ESR1 P03372 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1376189 0.88 FOLH1 (0.44) FOLH1
SCHEMBL5054600 0.83 FOLH1 (0.42) ALDH1A1FFAR4FFAR1FOLH1
SCHEMBL5058065 0.82 ALDH1A1 (0.45) ALDH1A1FFAR4FFAR1FOLH1GPR84
SCHEMBL5054708 0.82 ALDH1A1 (0.45) ALDH1A1FFAR4FFAR1FOLH1GPR84
SCHEMBL5053384 0.82 ALDH1A1 (0.45) ALDH1A1FFAR4FFAR1FOLH1GPR84
SCHEMBL5054290 0.78 FOLH1 (0.47) ALDH1A1FOLH1
SCHEMBL1373663 0.77 FOLH1 (0.41) FOLH1AKR1B1
SCHEMBL5059834 0.77 FOLH1 (0.46) ALDH1A1FOLH1PPARGPPARAHDAC11
SCHEMBL5060232 0.76 MAPT (0.45) ALDH1A1FOLH1HDAC11TSHR
SCHEMBL5051250 0.76 MAPT (0.45) ALDH1A1FOLH1HDAC11TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030064912-A1 Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors SLUSHER BARBARA S (US) 2003-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064912-A1 Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors NAALAD2, DNPEP, DPP9 ALDH1A1 736/4885FFAR4 3980/4885FFAR1 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.